Autres langues VISEN Pharmaceuticals

Actions

2561

KYG93Y5D1039

Recherche biotechnologique et médicale

Temps Différé Hong Kong S.E. 10:08:31 27/08/2026			Varia. 5j.	Varia. 1 janv.
19,98 ^HKD	-0,10%		+1,52%	-39,09%

26/06	VISEN Pharmaceuticals annonce des nominations au sein de son conseil d'administration, avec effet au 26 juin 2026	CI
18/05	VISEN Pharmaceuticals (SEHK:2561) lance un programme de rachat d'actions portant sur 11 392 686 titres, soit 10% de son capital social, en vertu de l'autorisation approuvée le 27 juin 2025.	CI

Autres langues

26/06	VISEN Pharmaceuticals Announces Board Appointments, Effective June 26, 2026
18/05	VISEN Pharmaceuticals commences an Equity Buyback Plan for 11,392,686 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2025.
24/04	WuXi Biologics Achieves Structural Completion and Key Equipment Arrival At Chengdu Microbial Commercial Manufacturing Site
20/03	Certain Shares of VISEN Pharmaceuticals are subject to a Lock-Up Agreement Ending on 20-MAR-2026.
12/03	Visen Pharmaceuticals posts loss for year of RMB253.4 million
12/03	VISEN Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025
26/01	Visen Pharmaceuticals says NMPA approves lonapegsomatropin (Skytrofa) for injection
26/01	VISEN Pharmaceuticals' Growth Hormone Replacement Therapy Approved in China
26/01	National Medical Products Administration Approves Biologics License Application for Lonapegsomatropin for Injection
13/10/25	VISEN Pharmaceuticals Appoints Lu Ying as the Chief Financial Officer, Effective from October 13, 2025
13/10/25	VISEN Pharmaceuticals Names CFO
13/10/25	Visen Pharmaceuticals appoints Lu Ying as CFO
22/09/25	VISEN Pharmaceuticals(SEHK:2561) added to S&P Global BMI Index
20/09/25	Certain Shares of VISEN Pharmaceuticals are subject to a Lock-Up Agreement Ending on 20-SEP-2025.
19/09/25	VISEN Pharmaceuticals Reports Earnings Results for the Half Year Ended June 30, 2025
17/09/25	25,269,136 Shares of VISEN Pharmaceuticals are subject to a Lock-Up Agreement Ending on 17-SEP-2025.
31/08/25	Visen Pharmaceuticals Announces Commercial Supply Framework Agreement with Visen HK and Ascendis Europe
28/08/25	VISEN Pharmaceuticals' H1 Loss Widens 41%
27/08/25	Visen Pharmaceuticals logs HY loss RMB118 mln
27/08/25	VISEN Pharmaceuticals Announces Board and Committee Changes, Effective August 27, 2025
27/06/25	Visen Pharmaceuticals Announces Directorate Changes, Effective 27 June 2025
09/06/25	WuXi Biologics Kicks Off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu
20/03/25	Visen Pharmaceuticals Says Number Of Offer Shares Under Global Offering 11.4 Million
12/03/25	VISEN Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024